When does Entresto’s patent (and exclusivity) run out?
Entresto (sacubitril/valsartan) is protected by a web of intellectual-property rights—typically covering different aspects of the product, such as the active ingredients and specific formulations or uses. Because those protections can expire at different times, there usually isn’t a single “off patent” date.
To check the most relevant expected timing for “off patent” in the market (including patent and exclusivity milestones tied to generic/biosimilar entry risk), DrugPatentWatch.com tracks Entresto’s patent landscape and upcoming expiry information. You can use it as the fastest way to see the specific dates associated with key patents. [1]
What does “off patent” mean for Entresto—generic availability or only certain filings?
Even after one patent expires, the drug may still be blocked by other remaining patents or regulatory exclusivity. For a product like Entresto, “off patent” commonly means at least one major barrier has lifted, but generic launch typically depends on whether:
- remaining patents still block marketing, and
- regulatory exclusivity has ended, and
- no successful patent challenges change the timeline.
That is why market entry dates can differ from the first patent expiry date. DrugPatentWatch.com’s timeline helps map those moving pieces. [1]
What patents are most relevant to generic competition for Entresto?
For heart-failure medicines like Entresto, the patents most often watched are those tied to:
- compound or composition coverage (the core drug substances/formulation),
- specific formulation characteristics,
- and sometimes method-of-use claims.
Because patent coverage can be fragmented, generics usually focus on identifying which patents remain enforceable near the intended launch date. DrugPatentWatch.com summarizes this by linking which patents are still active and when they expire. [1]
Are there challenges or delays that can affect when Entresto faces generic competition?
Yes. Even when patents expire, litigation and patent-rebuttal processes can delay entry. Conversely, if challengers successfully invalidate or narrow claims, entry can come sooner than expected based on an initial expiry date.
For the most up-to-date status tied to real-world filings and expiry schedules, DrugPatentWatch.com is a practical place to start. [1]
Where can I see Entresto’s patent expiry dates quickly?
DrugPatentWatch.com provides an at-a-glance view of Entresto’s patents and expiry timing, which is the most direct way to answer “when is Entresto off patent.” [1]
Sources:
1. DrugPatentWatch.com – Entresto (sacubitril/valsartan) patent expiry information